$4.68
-0.21 (-4.29%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VRCA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 6 with posted results
Held by 3 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 9.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)NCT07457918Incidence and severity of AEs including LSRs.Open-label · Treatment | Phase 3 | Recruiting | Combination product: Cantharidin | Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts | 600 | 2028-04-30 | in 620 d | 2026-05-05 |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)NCT07637734Proportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit.Randomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Combination product: VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan) | Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts | 300 | Aug 2027 | ≤ 377 d | 2026-06-10 |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)NCT07246590Proportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit.Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Combination product: VP-102, Vehicle | Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts | 300 | Jun 2027 | ≤ 315 d | 2026-01-21 |
| Open-Label Proof of Concept Study of VP-315 in Basal Cell CarcinomaNCT05188729results2025-06-18Part 1: Percentage of Subjects With Discontinuations Due to Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose | Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma | 92 | 2024-04-15actual | — | 2025-06-18 |
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital WartsNCT03981822results2021-09-22Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Combination product: VP-102 and applicator, Placebo | Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts | 105 | 2020-05-21actual | — | 2024-11-27 |
| Cantharidin and Occlusion in Verruca EpitheliumNCT03487549results2021-09-01Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Combination product: VP-102 Cantharidin topical film forming solution, VP-102 Cantharidin, topical film forming solution | Common Wart, Warts Hand, Warts, Papillomavirus Infections, DNA Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Virus Diseases, Tumor Virus Infections, Verruca Vulgaris, Verruca | 56 | 2019-05-16actual | — | 2024-11-27 |
| Cantharidin Application in Molluscum Patients-1NCT03377790results2021-12-14Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Combination product: VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102 | Molluscum Contagiosum | 266 | 2018-11-26actual | — | 2022-01-11 |
| Cantharidin Application in Molluscum PatientsNCT03377803results2021-12-14Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Combination product: VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102 | Molluscum Contagiosum | 262 | 2018-09-26actual | — | 2021-12-14 |
| Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.NCT03186378results2021-08-09The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102.Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Combination product: VP-102 with applicator | Molluscum Contagiosum | 33 | 2018-06-25actual | — | 2021-08-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19